The U.S. Department of Health and Human Services released guidance clarifying how manufacturers can sell drugs directly to consumers through the proposed TrumpRx platform while complying with the federal anti‑kickback statute. The agency also outlined ways hospitals could receive incentives for buying U.S.‑made drugs under a proposed CMS rule. HHS aims to enable direct‑to‑consumer pricing models and expand domestic sourcing without triggering criminal anti‑kickback liability, a move intended to accelerate the administration’s TrumpRx rollout. The guidance reduces legal uncertainty for companies considering direct distribution channels and signals policy support for alternative pricing and supply‑chain approaches.